Company intelligence / Profile preview

Kotobuki Pharmaceutical

Sakaki-machi, Nagano, Japankotobuki-pharm.co.jp ↗

Ownership: Private
Employees: ~130
Development stage: Other

Overview

Kotobuki Pharmaceutical has a history of developing both original and generic pharmaceuticals. Notably, it co-developed the SGLT2 inhibitor ipragliflozin ("Suglat") for type II diabetes with Astellas Pharma. The company also contributed to the development of gilteritinib ("Xospata"), an FLT3 inhibitor for relapsed/refractory acute myeloid leukemia—now FDA-approved through Astellas. Other marketed drugs include treatments for gastrointestinal disorders, pain management, neurological diseases, and metabolic conditions.

Therapeutic areas: GastroenterologyEndocrinologyOncologyNeurology
Modalities: Small moleculeCombination drugsFormulation technology-based products
Industry: Biotech

Partnerships

Astellas PharmaAjinomoto

Beyond the preview

Go deeper on Kotobuki Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kotobuki Pharmaceutical.

Explore the full profile